CD258/LIGHT/TNFSF14
Alpha Lifetech can provide CD258/LIGHT/TNFSF14 corresponding products, help each customer's research and development.
01
Introduction To CD258/LIGHT/TNFSF14
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD258/LIGHT/TNFSF14 protein is a common target in medicine.
LIGHT, also known as tumor necrosis factor superfamily member 14 (TNFSF14 / CD258), is a type II transmembrane protein containing a C-terminal TNF homology domain folded into a β folding sandwich, which asset into a functional homotrimer. It is mainly expressed in activated T cells, natural killer (NK) cells, and immature dendritic cells (DC), which promotes the formation of TLS in tumor tissues by inducing the normalization of tumor blood vessels and the formation of high endothelial veins. LIGHT plays a key regulatory role in the recruitment and activation of immune cells in tumor lesions.
Function of Target CD258/LIGHT/TNFSF14
TNFSF14 plays a key regulatory role in the immune response, but its role varies in different diseases. As a costimulatory factor for lymphocyte activation, TNFSF14 plays an important role in the development and homeostasis of T cells and the maturation of dendritic cells. When the host is infected with adenovirus, TNFSF14 can serve as an inflammatory biomarker indicating the presence of adenovirus infection in the host and the extent of disease caused by viral infection. When the host is infected with the influenza virus, TNFSF14-HVEM signaling can stimulate the maturation and proliferation of memory CD8 T cells, helping the host immune system to provoke a second immune response. During hepatitis virus infection, TNFSF14 acts as a proinflammatory factor, involved in inflammation and causing tissue damage. Meanwhile, TNFSF14 was able to stimulate the proliferation of T cells and cause the apoptosis of various tumor cells.
Gene Pathway of Target CD258/LIGHT/TNFSF14
The LIGHT-HVEM pathway is an important co-signaling pathway in T cells, and the LIGHT-LT β R promotes immune responses by creating a tissue microenvironment to alter the function of dendritic cells and stromal cells. TNFSF14 Also participates in the dominant pathway of LT β R-NIK-p52 NF- κ B, promoting the inflammatory gene expression and regulating the inflammatory response. This pathway can promote the formation of inflammatory esophageal fibroblasts in vitro and downregulate homeostatic factors such as WNT, BMP, and type 3 signaling proteins. TNFSF14 NK cells can stimulate IFN γ production through the nuclear factor- κ B (NF κ B) RelA / p50 signaling pathway. This pathway plays an important role in maintaining CD8 + effector T cell function and triggering apoptosis of various tumor cells.
Fig 1: LIGHT Gene Pathway. (Reference source: Ware CF. Targeting the LIGHT-HVEM pathway. Adv Exp Med Biol. 2009;647:146-55. )
Alpha Lifetech Can Provide
At present, various drugs targeting CD258/LIGHT/TNFSF14 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method, and remarkable achievements have been made. CD258/LIGHT/TNFSF14 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD258/LIGHT/TNFSF14 protein products are also essential. Alpha Lifetech can provide CD258/LIGHT/TNFSF14 corresponding products and help each customer's research and development. In addition, Alpha Lifetech can provide efficient and accurate EC50 / IC50, helping customer companies to screen compounds efficiently and accurately. At the same time, Alpha Lifetech also provides some services such as recombinant antibody production and recombinant antibody purification, to conduct in vitro affinity screening to ensure the maturity of recombinant antibody affinity and help customers in antibody drug discovery, and subsequent various experiments.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64617 | 50ug,100ug,500ug | |
| ALP64551 | 50ug,100ug,500ug | |
Reference
[1] Skeate JG, Otsmaa ME, Prins R, Fernandez DJ, Da Silva DM, Kast WM. TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy. Front Immunol. 2020 May 15;11:922.
[2] del Rio ML, Fernandez-Renedo C, Chaloin O, Scheu S, Pfeffer K, Shintani Y, Perez-Simon JA, Schneider P, Rodriguez-Barbosa JI. Immunotherapeutic targeting of the LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells. MAbs. 2016;8(3):478-90.
[3] Maña P, Liñares D, Silva DG, Fordham S, Scheu S, Pfeffer K, Staykova M, Bertram EM. LIGHT (TNFSF14/CD258) is a decisive factor for recovery from experimental autoimmune encephalomyelitis. J Immunol. 2013 Jul 1;191(1):154-63.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102